Novartis Ag (NVS) Liabilities and Shareholders Equity (2009 - 2026)

Novartis Ag has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $122.0 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 16.9% year-over-year to $122.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $233.0 billion (up 12.75% YoY) and the FY2025 annual result came in at $110.9 billion, up 8.51% from the prior year.
• Liabilities and Shareholders Equity climbed to $122.0 billion in Q2 2026 per NVS's latest filing, from $110.9 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $122.9 billion in Q2 2022 and troughed at $97.5 billion in Q2 2024.
• A 5-year average of $109.8 billion and a median of $110.9 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity decreased 14.91% in 2023, then gained 16.9% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $117.5 billion in 2022, then retreated by 14.91% to $99.9 billion in 2023, then grew by 2.3% to $102.2 billion in 2024, then advanced by 8.51% to $110.9 billion in 2025, then grew by 9.99% to $122.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $122.0 billion, $110.9 billion, and $104.4 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.